Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York.
A live webcast and replay will be available for at least 30 days on the Events page of Caribou’s website.
Caribou Biosciences (Nasdaq: CRBU) will feature its allogeneic CAR-T programs vispa-cel and CB-011 in oral presentations at the 2026 European Hematology Association Annual Meeting in Stockholm, June 11-14, 2026.
Presentations cover ANTLER and CaMMouflage phase 1 trials in lymphoma and multiple myeloma.
Caribou Biosciences (Nasdaq: CRBU) reported Q1 2026 results and clinical updates on May 7, 2026. Key items: FDA alignment on the pivotal ANTLER-3 vispa-cel trial design; RMAT designation for CB-011 with strong early response rates; Q1 cash of $118.6M and cash runway into 2H 2027.
Company expects longer follow-up data for vispa-cel and CB-011 in 2026 and is exploring funding options for the vispa-cel pivotal trial.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026 at 8:40am PT in Las Vegas.
Webcast details and replay access are available via the company Events page; webcasts remain available for at least 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU) announced the FDA granted RMAT designation to CB-011, an allogeneic anti-BCMA CAR-T for relapsed or refractory multiple myeloma.
RMAT follows promising CaMMouflage phase 1 dose‑escalation data: 92% ORR, 75% ≥CR, and 91% MRD negativity in 12 BCMA‑naïve patients at the recommended dose for expansion; dose expansion and additional 2026 data planned.
Caribou Biosciences (Nasdaq: CRBU) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Key financials: FY2025 licensing revenue $11.2M, GAAP net loss $148.1M ($1.59/sh), non-recurring impairment $21.3M and $142.8M cash at year-end. Management expects cash to fund operations into 2H 2027 while exploring options to fully fund a vispa-cel pivotal trial.
Clinical: vispa-cel showed efficacy and durability in 2L LBCL comparable to autologous CAR-T; Caribou is engaging the FDA on pivotal design. CB-011 dose expansion for r/r multiple myeloma initiated with planned data updates in 2026.
Caribou Biosciences (Nasdaq: CRBU) said management will attend two investor conferences in February–March 2026. Key engagements include a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Feb 19, 2026 at 10:45 AM ET and a fireside chat at the Leerink Global Healthcare Conference in Miami on Mar 10, 2026 at 8:00 AM ET.
A webcast of the Leerink presentation will be available via the company Events page and accessible for at least 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU) announced late-breaking presentations at the 2026 Tandem Meetings (Feb 4-7, Salt Lake City) featuring updated clinical and new translational data for two allogeneic CAR-T programs.
Vispa-cel (CB-010) ANTLER poster (Feb 5) reports efficacy and durability reportedly on par with autologous CAR-T in second-line large B cell lymphoma. CB-011 CaMMouflage oral (Feb 7) shows CAR-T expansion correlating with deep, durable responses and supports the selected regimen for dose expansion. Abstracts are available at tandemmeetings.com and presentations will be posted on Caribou’s Scientific Publications page after the event.
Caribou Biosciences (Nasdaq: CRBU) will host an in-person and virtual KOL panel at the 67th ASH Annual Meeting on Dec 6, 2025 at 7:30 AM ET to discuss vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy. The session will examine how vispa-cel may broaden access to second-line large B cell lymphoma care by enabling CAR-T delivery in community hospitals and academic centers.
The event is moderated by Tina Albertson, MD, PhD, and features clinicians from Utah Cancer Specialists, Bozeman Health, Medical College of Wisconsin, and University of Kansas Cancer Center. In-person attendance is invite-only; a webcast and replay will be available and registration is on the company Events page.
Caribou Biosciences (Nasdaq: CRBU) reported Q3 2025 results and clinical updates on Nov 12, 2025. Key clinical data show vispa-cel (CB-010) ANTLER phase 1 confirmatory cohort (N=22) achieved 82% ORR, 64% CR, and 51% 12‑month PFS (data cutoff Sep 29, 2025). An optimized vispa-cel profile (N=35) showed 86% ORR, 63% CR, and 53% 12‑month PFS (median follow‑up 11.8 months).
CB-011 (CaMMouflage phase 1) dose‑escalation RDE 450M cells; BCMA‑naïve RDE cohort (12 pts, cutoff Sep 24, 2025) showed 92% ORR, 75% ≥CR, and 91% MRD‑negativity (10/11 evaluable). Company had $159.2M cash and expects funding into 2H 2027 while exploring options to fully fund pivotal vispa-cel trial.